

APPLICANTS: Ward et al.
SERIAL NO: 10/719,370

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

AMENDMENT TO THE CLAIMS: This listing of claims replaces all prior versions and listings of claims in the instant patent application.

Listing of claims:

1. (Currently amended) A compound ~~8 to 80~~ 12 to 50 nucleobases in length targeted to a nucleic acid molecule encoding HIF1 α (SEQ ID NO: 133), wherein said compound comprises at least an 8-nucleobase portion of SEQ ID NO: ~~189 or 446~~, and ~~wherein said compound~~ and specifically hybridizes with said nucleic acid molecule encoding HIF1 α ~~and inhibits the expression of HIF1 α~~ .
2. (Canceled)
3. (Currently amended) The compound of ~~claim 2 comprising~~ claim 1 which is 15 to 30 nucleobases in length.
4. (Original) The compound of claim 1 comprising an oligonucleotide.
5. (Original) The compound of claim 4 comprising an antisense oligonucleotide.
6. (Original) The compound of claim 4 comprising a DNA oligonucleotide.
7. (Original) The compound of claim 4 comprising an RNA oligonucleotide.
8. (Original) The compound of claim 4 comprising a chimeric oligonucleotide.
- 9-21. (Canceled)
22. (Original) The compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.
23. (Original) The compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.
24. (Original) The compound of claim 1 having at least one phosphorothioate internucleoside linkage.
25. (Original) The compound of claim 1 having at least one 5-methylcytosine.
- 26-32. (Canceled)
33. (Original) A method of inhibiting the expression of HIF1 α in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of HIF1 α is inhibited.

APPLICANTS: Ward et al.
SERIAL NO: 10/719,370

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

- 34-36. (Canceled)
37. (Original) A kit or assay device comprising the compound of claim 1.
38. (Original) A method of treating an animal having a disease or condition associated with HIF1 α comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of HIF1 α is inhibited.
39. (Original) The method of claim 38 wherein the disease or condition is a hyperproliferative disorder.
40. (Original) The method of claim 39 wherein the hyperproliferative disorder is cancer.
41. (Original) The method of claim 40 wherein the cancer carries a p53 mutation.
42. (Original) The method of claim 39 wherein the hyperproliferative disorder is an angiogenic disorder.
43. (Original) The method of claim 42 wherein the angiogenic disorder affects the eye.
44. (Original) A composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.
- 45-118. (Canceled)
119. (Currently amended) The compound of ~~claim 118~~ claim 1 with a nucleotide sequence consisting of SEQ ID NO: 446.
120. (Previously presented) The compound of claim 1 having 100% complementarity with the nucleic acid molecule encoding HIF1 α
121. (Canceled)
122. (New) An antisense oligonucleotide 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleobases in length targeted to a nucleic acid molecule encoding HIF1-alpha (SEQ ID NO: 133), wherein said compound has at least 80% identity with SEQ ID NO: 446.
123. (New) The antisense oligonucleotide of claim 122 which is 18, 19, 20, 21 or 22 nucleobases in length and has at least 90% identity with SEQ ID NO: 446.
124. (New) The antisense oligonucleotide of claim 123 which is 19, 20 or 21

APPLICANTS: Ward et al.
SERIAL NO: 10/719,370

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

nucleobases in length and has at least 95% identity with SEQ ID NO: 446.